• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Correspondence Radiotherapy for breast cancer, the TARGIT-A trial
Javant Vaidya and colleagues report an increased risk of non-breast cancer deaths with external beam radiotherapy (EBRT) compared with intraoperative radiotherapy, highlighting the difference in cardiac events in the two treatment groups. Although the log-rank statistics show a significant difference in non-breast cancer deaths in the EBRT group, these deaths included stroke, bowel ischaemia, and other events unrelated to breast irradiation. Therefore, the number of cardiac events are small, and to suggest that the risk of cardiac death differs between EBRT and intraoperative radiotherapy would be premature.
Source: LANCET - May 16, 2014 Category: Journals (General) Authors: Penny Mackenzie, Anthony Fyles, Caroline Chung Tags: Correspondence Source Type: research